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Abstract
This article reviews the impact of medical therapy on the risk of atherosclerotic coronary artery disease.
	 SA	Fam	Pract	2010;52(4):305-306
Background
It is estimated that at the age of 40 years, the life-time risk to 
develop coronary artery disease is one in two for men and 
one in three for women.1 Atherosclerotic coronary artery 
disease begins in childhood and the risk factors influence 
the development of atherosclerosis throughout one’s 
lifetime.2
A standardised case-control study of acute myocardial 
infarction in 52 countries, representing every inhabited 
continent, demonstrated that nine cardiovascular risk factors 
in all the countries are responsible for 90% of the population 
attributable risk in men and 94% in women: dyslipidaemia, 
hypertension, smoking, diabetes, abdominal obesity, diet 
poor in daily consumption of fruit and vegetables, lack of 
regular physical activity, lack of daily alcohol intake and 
psychological factors (mainly depression).3 
An elevated cholesterol is the driving force of atherogenesis. 
Evidence indicates that a life-time low LDL-cholesterol level 
lowers the risk of atherosclerotic coronary artery disease by 
up to 80% compared with the general population. Intensive 
LDL-lowering therapy reduces the risk of atherosclerotic 
heart disease by 40% to 50%.4
What is happening globally?
In industrialised countries the rates of heart-disease 
related deaths are reducing due to lipid lowering therapy, 
hypertension treatment and a reduction in smoking. The 
largest contribution came from secondary preventive 
treatments for patients after myocardial infarction and 
revascularisation. Each death avoided by treating a 
patient with recognised coronary heart disease can yield 
an additional 7.5 years of life. Risk factor reduction has 
been shown to account for up to 79% of the total life-
years gained in certain populations. The question to ask? 
Would it not be much more beneficial to start much earlier 
in a person’s life to reduce the impact of cardiovascular risk 
factors by early recognition and treatment. New trends are 
emerging: increase in prevalence of hypertension, obesity 
and diabetes mellitus5 in contrast to developing countries 
in which the prevalence of atherosclerotic-related heart 
disease is increasing.
What works in therapy?
Cessation of smoking is associated with a relative risk 
reduction in mortality of up to 36%.6 The benefits of 
smoking cessation are greater and accrue more rapidly in 
comparison to other important cardiovascular interventions. 
Patients who survived a myocardial infarction and then quit 
smoking reduce their mortality risk by 37% [95% CI 18 to 
52%] as compared to persistent smokers. Observational 
studies persistently reported a decreased number of 
coronary heart disease events in people who perform 
regular aerobic activity. Even one hour of walking per week 
is associated with a lower risk.
Reducing LDL-cholesterol by about 1.5 mmol/L reduces by 
about a third the incidence of ischaemic heart disease and 
ischaemic stroke independently of age or blood pressure.7
Reducing dietary salt by 3 g per day can reduce blood 
pressure, new cases of coronary heart disease, stroke and 
deaths to a similar level as the effect of other risk factor 
reduction.8
Aspirin used for primary prevention can reduce the relative 
risk of a non-fatal myocardial infarction by 23%, but has no 
effect on mortality. In secondary prevention aspirin reduces 
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the risk of non-fatal myocardial infarction by about 31% and 
the relative risk of death by 9%.9
Niacin can reduce major coronary events by ± 25% 
(95% CI 13 to 35%) according to a meta-analysis.10 In 
patients with stable ischaemic (coronary) heart disease and 
a normal left ventricular ejection fraction, a meta-analysis 
showed that ACE-inhibitors reduced relative risk of mortality 
by 13% (95% CI 6 to 19%) and non-fatal myocardial 
infarction by 17% (95% CI 6 to 27%).11 In the same meta-
analysis angiotensin receptor blockers reduce a composite 
of cardiovascular mortality, non-fatal myocardial infarction 
and stroke by 12% (95% CI 0 to 25%). Beta-blockers, used 
as a secondary prevention measure, can reduce mortality 
and reinfarction by up to 23% (95% CI 16 to 30%).12
The use of N-3 polyunsaturated fatty acids after a myocardial 
infarction results in a 45% reduction in sudden death and a 
30% reduction in cardiovascular death.13
How effective is optimal medical 
therapy?
In a large trial, the use of five drugs [aspirin, clopidogrel, 
beta-blocker, statin renin-angiotensin system blocker 
(ACE-I/ARB)] was tested versus the use of one of these 
drugs or none in survivors of a first acute myocardial infarct. 
The use of the five drugs reduced relative risk of mortality at 
one year by 74% (95% CI 62 to 82%)13 versus one or alone 
of the drugs used.14
In the chronic artery disease setting, non-adherence to 
cardio protective medications (beta-blockers, statins, ACE-
inhibitors) was associated with a 10–40% relative increase 
in risk of cardiac hospitalisations and a 50–80% relative 
increase in mortality.15
What does not work?16
Dietary supplements, herbal preparations and alternative 
therapies are popular with patients, but they are of 
dubious benefit. The data for most such interventions are 
inconclusive.
Vitamin E supplements and antioxidant therapy for primary 
and secondary prevention of atherosclerotic cardiovascular 
events had no effect and even suggested increased 
mortality with use of 
Vitamin E. Garlic, when tested versus placebo, had no effect 
on LDL-cholesterol levels.
Reducing homocysteine levels by using folic acid and 
B-vitamins has not shown any benefit in many randomised 
trials.
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